Greenvale, NY September 15, 2011

Redox Pharmaceutical Corporation, a New York based company announced the granting of a new United States patent on the use of CTC-96 (Doxovir™) for the treatment of psoriasis. The patent covers the use of CTC-96 to inactivate certain Zinc containing proteins that are elevated in psoriasis, such as Glis1, and which lead to abnormal proliferation of skin cells.

“We are very pleased to have received this new patent which paves the way for us to further extend the development of Doxovir™ as a novel dermatologic medicine” says Mel Dubin, Chairman and CEO of Redox. “Psoriasis is a vexing, very widespread disease which affects 2-3% of the population” says Mr Dubin,.“and we believe that as a non-steroidal topical treatment for mild to moderate psoriasis Doxovir™ can be an effective addition to the current treatments on the market”.

Clinical Trials on Herpes Labialis (cold sores):

• Phase Ib Clinical Trials have been successfully completed.
• Phase II Clinical Trials have been successfully completed.

Clinical Trials on Ophthalmic Herpetic Keratitis and Adenoviral conjunctivitis (pink eye):

• Phase I Clinical Trials for these two ophthalmic applications have been successfully completed.
• Phase II Clinical Trials for both ophthalmic Herpetic Keratitis and ocular Adenoviral conjunctivitis (pink eye) are currently being planned.